HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hip Fractures (Intertrochanteric Fractures)

Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
Also Known As:
Intertrochanteric Fractures; Femoral Trochlear Fracture; Femur Trochlear Fracture; Femur Trochlear Fractures; Fracture, Femoral Trochlear; Fracture, Femur Trochlear; Fractures, Femoral Trochlear; Fractures, Femur Trochlear; Fractures, Hip; Fractures, Intertrochanteric; Fractures, Subtrochanteric; Fractures, Trochanteric; Trochlear Fracture, Femoral; Trochlear Fracture, Femur; Trochlear Fractures, Femoral; Femoral Trochlear Fractures; Subtrochanteric Fractures; Trochanteric Fractures; Trochlear Fractures, Femur
Networked: 3254 relevant articles (184 outcomes, 633 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Osteoporosis
2. Pain (Aches)
3. Wounds and Injuries (Trauma)
4. Postmenopausal Osteoporosis
5. Bone Resorption

Experts

1. Iwamoto, Jun: 22 articles (11/2019 - 01/2005)
2. Parker, M J: 21 articles (04/2021 - 01/2000)
3. Sato, Yoshihiro: 19 articles (11/2019 - 01/2005)
4. Parker, Martyn J: 17 articles (01/2022 - 09/2005)
5. Bhandari, Mohit: 13 articles (01/2022 - 01/2004)
6. Cauley, Jane A: 12 articles (01/2016 - 05/2003)
7. Kiel, Douglas P: 11 articles (06/2022 - 05/2006)
8. Ha, Yong-Chan: 11 articles (05/2022 - 06/2011)
9. Bauer, Douglas C: 10 articles (06/2015 - 04/2003)
10. Reginster, Jean-Yves: 9 articles (01/2020 - 04/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hip Fractures:
1. Diphosphonates (Bisphosphonates)IBA
01/01/2023 - "Postmenopausal females in a primary prevention population defined as <50% prevalence of prior fragility fracture (median 16.9%, range 0 to 48% when reported in the trials) and at risk of fragility fracture, treatment with bisphosphonates as a class (median 2 years, range 1-6 years) probably reduces the risk of clinical fragility fractures (19 RCTs, n = 22,482, ARD = 11.1 fewer in 1000, 95% CI 15.0-6.6 fewer, [number needed to treat for an additional beneficial outcome] NNT = 90), and may reduce the risk of hip fractures (14 RCTs, n = 21,038, ARD = 2.9 fewer in 1000, 95% CI 4.6-0.9 fewer, NNT = 345) and clinical vertebral fractures (11 RCTs, n = 8921, ARD = 10.0 fewer in 1000, 95% CI 14.0-3.9 fewer, NNT = 100); it may not reduce all-cause mortality. "
03/01/2017 - "Whilst they have proved effective in this role, there is growing concern over their long-term use, with much evidence linking bisphosphonate-related suppression of bone remodelling to an increased risk of atypical subtrochanteric fractures of the femur (AFFs). "
07/01/2013 - "Compliant use of bisphosphonate is effective in the prevention of second hip fractures."
01/01/2020 - "The four non-bisphosphonates interventions studied also showed statistically significant benefit relative to placebo for FN BMD, and for hip fractures TPTD, ROMO followed by ALN, and DEN showed statistically significant benefit relative to placebo. "
01/01/2010 - "There is currently no valid basis for distinguishing in a formal and objective manner the different new-generation bisphosphonates, in terms of efficacy against either vertebral, peripheral or hip fractures. "
2. Alendronate (Alendronate Sodium)FDA LinkGeneric
3. Vitamin DFDA LinkGeneric
4. Risedronic Acid (Actonel)FDA LinkGeneric
5. CalciumIBA
6. DenosumabFDA Link
7. Tranexamic Acid (AMCA)FDA Link
8. Zoledronic Acid (Zometa)FDA Link
9. strontium ranelate (protelos)IBA
10. Teriparatide (Parathar)FDA Link

Therapies and Procedures

1. Therapeutics
2. Intramedullary Fracture Fixation
3. Length of Stay
4. Traction
5. Arthroplasty